We are vaccinating patients ages 16+. Learn more:
Vaccines | Testing | Patient Care | Visitor Guidelines | Coronavirus | Self-Checker | Email Alerts
advance to content
The immune system sometimes has difficulty fighting cancer, either because it doesn't recognize cancer cells as "foreign," or there isn't a strong enough immune presence to overtake cancer cells' rapid growth.
Researchers at BKI are developing drugs and vaccines that trigger the immune system's natural defenses to kick in and kill cancer.
Some cancers apply the brakes (for example, PD-1) to the immune system. As a result, the immune system can't fight the cancer.
Anti-PD-1 immunotherapies disable the brakes, allowing the immune system to fight the cancer under its own momentum.
Other cancers require the brakes to be disabled and for the immune system to be accelerated.
Doctors use a combination of therapies to release the brakes and to press the accelerator on the immune system.
These more challenging cancers really need the accelerator to be pushed hard after disabling the brakes.
They may require combinations of therapies, including cancer vaccines and a variety of immunotherapies.
Immune checkpoint blockers are drugs that prevent cancer cells from producing certain types of proteins ("checkpoints"). This allows the immune system to see and attack these cancers.
Types of cancer respond to this immunotherapy. Some patients have seen their cancer go from stage 4 to undetectable. Others have had tumors shrink drastically and stay that way for years.
Anti-PD-1 therapy, a type of checkpoint inhibitor drug, was developed at the Johns Hopkins Kimmel Cancer Center.
Years of basic research at Johns Hopkins and BKI led to the development of leading checkpoint inhibitor drugs.
Therapeutic cancer vaccines supercharge the immune system by calling immune cells to the tumor site and causing them to seek out and kill cancer cells throughout the body.
Therapeutic vaccines are different from preventive vaccines, like the HPV vaccine, or the measles vaccine. Preventive vaccines are given to healthy people and are not a form of immunotherapy. Therapeutic vaccines are given to people who already have a disease — to help their bodies' own defenses fight off the illness.
A vaccine for pancreatic cancer developed by cancer researchers at Johns Hopkins is being tested in clinical trials at the Johns Hopkins Kimmel Cancer Center.
There are a few different approaches to using the vaccine: Give it before surgery; combine it with other immune-modulating drugs; or add a second kind of vaccine, a weakened version of the bacterium listeria.
Johns Hopkins investigators are also exploring therapeutic vaccines that can be used for breast, colon, ovarian and lung cancers.
Personalized cell therapy, also called adoptive T cell therapy, is a form of immunotherapy that increases the number of disease-fighting immune cells in the body.
With this approach, T cells are collected from a patient and grown or treated with antibodies in a laboratory. The cells are then infused back into the patient's bloodstream, where they fight off infections or cancer cells.
At Johns Hopkins, researchers have developed a new type of adoptive T cell therapy focused on treating high-risk multiple myeloma patients. The procedure collects a specific type of T cell from the bone marrow, called marrow-infiltrating lymphocytes (MILs), and then uses the MILs in combination with chemotherapy and a stem cell transplant to treat and control the cancer.
Bone Marrow is the factory for blood and immune cells. Bone marrow makes 500 billion blood and immune cells each day.
Bone marrow contains special immune cells that are primed to fight specific types of cancer.
